Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

NCT06948084 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

NIH

Sponsor class

Conditions

Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Biopsy
DRUG: Carfilzomib
PROCEDURE: Computed Tomography
DRUG: Daratumumab and Recombinant Human Hyaluronidase
DRUG: Dexamethasone
PROCEDURE: FDG-Positron Emission Tomography
DRUG: Pomalidomide
DRUG: Teclistamab

Sponsor

National Cancer Institute (NCI)